Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone

Therapies that target cancer cells may have unexpected effects on the tumor microenvironment that affects therapy outcomes or render therapy resistance. Prostate cancer (PCa) bone metastasis is uniquely associated with osteoblastic bone lesions and treatment with cabozantinib, a VEGFR-2 and MET inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kai-Jie, Li, Jeffrey K., Lee, Yu-Chen, Yu, Guoyu, Lin, Song-Chang, Pan, Tianhong, Satcher, Robert L., Titus, Mark A., Yu-Lee, Li-Yuan, Weng, Wen Hui, Gallick, Gary E., Lin, Sue-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650395/
https://www.ncbi.nlm.nih.gov/pubmed/29088840
http://dx.doi.org/10.18632/oncotarget.20489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650395/
https://www.ncbi.nlm.nih.gov/pubmed/29088840
http://dx.doi.org/10.18632/oncotarget.20489

Ejemplares similares